Corcept Therapeutics Inc
Suletud
SektorTervishoid
74.19 1.2
Ülevaade
Aktsiahinna muutus
24h
Min
71.31
Max
76.23
Sissetulek | 75M 43M |
|---|---|
Müük | 91M 256M |
P/E Sektori keskmine | 178.8 51.78 |
Aktsiakasum | 0.36 |
Kasumimarginaal | 16.782 |
Töötajad | 730 |
EBITDA | 91M 47M |
Soovitused | Tugev "osta" hinnang |
|---|---|
12 kuu keskmine prognoos | +127.77% upside |
Turukapital | -1.1B 8.7B |
|---|---|
Eelmine avamishind | 72.99 |
Eelmine sulgemishind | 74.19 |
Corcept Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Corcept Therapeutics Inc Prognoos
Hinnasiht
By TipRanks
127.77% tõus
12 kuu keskmine prognoos
Keskmine 165.75 USD 127.77%
Kõrge 173 USD
Madal 161 USD
Põhineb 4 Wall Streeti analüütiku instrumendi Corcept Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Corcept Therapeutics Inc
Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.